239 related articles for article (PubMed ID: 31108227)
1. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis.
Singh S; Proudfoot JA; Dulai PS; Xu R; Feagan BG; Sandborn WJ; Jairath V
Clin Gastroenterol Hepatol; 2020 Feb; 18(2):424-431.e7. PubMed ID: 31108227
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
3. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.
Singh S; Proudfoot JA; Dulai PS; Jairath V; Fumery M; Xu R; Feagan BG; Sandborn WJ
Am J Gastroenterol; 2018 Aug; 113(8):1197-1205. PubMed ID: 29925913
[TBL] [Abstract][Full Text] [Related]
4. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
Hibi T; Imai Y; Senoo A; Ohta K; Ukyo Y
J Gastroenterol; 2017 Oct; 52(10):1101-1111. PubMed ID: 28324167
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
Thorlund K; Druyts E; Toor K; Mills EJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
[TBL] [Abstract][Full Text] [Related]
8. Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials.
Agrawal M; Petralia F; Tepler A; Durbin L; Reinisch W; Colombel JF; Shah SC
Inflamm Bowel Dis; 2023 Jan; 29(1):1-8. PubMed ID: 35366313
[TBL] [Abstract][Full Text] [Related]
9. Infliximab for induction and maintenance therapy for ulcerative colitis.
Rutgeerts P; Sandborn WJ; Feagan BG; Reinisch W; Olson A; Johanns J; Travers S; Rachmilewitz D; Hanauer SB; Lichtenstein GR; de Villiers WJ; Present D; Sands BE; Colombel JF
N Engl J Med; 2005 Dec; 353(23):2462-76. PubMed ID: 16339095
[TBL] [Abstract][Full Text] [Related]
10. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
[TBL] [Abstract][Full Text] [Related]
12. Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab.
Reinisch W; Colombel JF; Gibson PR; Rutgeerts P; Sandborn WJ; Tarabar D; Huyck S; Khalifa A; Marano C; Philip G; Yao R; Zhang H; Cornillie F
Inflamm Bowel Dis; 2019 Jan; 25(1):163-171. PubMed ID: 29982631
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.
Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1050-1060.e9. PubMed ID: 36029969
[TBL] [Abstract][Full Text] [Related]
14. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
Toor K; Druyts E; Jansen JP; Thorlund K
J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study.
Wong ECL; Merat S; Monaco C; Dulai PS; Jairath V; Marshall JK; Reinisch W; Narula N
Dig Dis Sci; 2023 Jun; 68(6):2635-2646. PubMed ID: 37119375
[TBL] [Abstract][Full Text] [Related]
16. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.
Thukral C; Cheifetz A; Peppercorn MA
Drugs; 2006; 66(16):2059-65. PubMed ID: 17112300
[TBL] [Abstract][Full Text] [Related]
18. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
Rutgeerts P; Feagan BG; Marano CW; Padgett L; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Zhang H; Colombel JF; Reinisch W; Gibson PR; Sandborn WJ;
Aliment Pharmacol Ther; 2015 Sep; 42(5):504-14. PubMed ID: 26119226
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis: A case report.
Alhalabi M; Eddin KA; Cheha K; Abbas A
Medicine (Baltimore); 2021 Sep; 100(38):e27283. PubMed ID: 34559136
[TBL] [Abstract][Full Text] [Related]
20. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Lawson MM; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]